-
April 2026: This Month in Huntington’s Disease Research
Latest News
-
Gone fishing: protein network screen identifies new therapeutic targets in Huntington's disease
'Discovery-driven' screen reveals new protein networks involved in Huntington's disease damage & new drug targets
-
Prana Biotech publishes Huntington's disease animal model data for PBT2
Prana Biotechnology has released data demonstrating their drug, PBT2, is effective in animal models of HD
-
'Guard dog' proteins reveal surprising connections between Huntington's disease and other brain disorders
DNA/RNA-binding proteins may be involved in the damage caused by Huntington's disease and other major brain disorders
-
Dyeing to prevent dying? Methylene blue beneficial in Huntington's disease mice
A bolt from the blue – methylene blue may fight Huntington's disease by preventing protein clumps
-
Prominent Huntington's disease researcher "fabricated data" in grant applications
Noted Huntington's disease researcher found to have falsified data on grant applications – but published findings sta
-
Calming down the immune system helps Huntington's disease mice
CB2-activating drug improves survival and symptoms in Huntington's disease mice through calming down the immune syste
-
Targeting oxidative stress in Huntington's Disease
Damage to cells caused by oxidative stress is part of HD – could a new targeted drug help reduce this problem?
-
Of mice and men: using animal models to study Huntington's disease
Animal models of Huntington's disease: what they tell us about the disease and how can they help develop new therapie
-
HDBuzz Prize runner-up 2012: Fruit flies, faulty connections and Huntington's disease
Recent study in fruit flies identifies a new connection between synapses and HD
-
Illuminating findings in blood cells from Huntington's disease patients
Levels of the huntingtin protein can be directly measured in blood – could this be useful for gene silencing studies?
HDBuzz Trial Tracker
Sites for Phase 3 trial for votoplam, INVEST-HD, now open. Updates on recruitment and first dosing imminent.
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
